Seviprotimut L Uses, Dosage, Side Effects and more
Seviprotimut L is under investigation in clinical trial NCT01546571 (Study of a Melanoma Vaccine in Stage Iib, Iic, and III Melanoma Patients).
| Trade Name | Seviprotimut L |
| Generic | Seviprotimut-L |
| Seviprotimut-L Other Names | Human polyvalent shedded antigen vaccine, Seviprotimut L, Seviprotimut-L |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
